Evidence map›Paper›PMID 28927454›Full record

ArticleAnnals of clinical microbiology and antimicrobials2017

Extended spectrum beta-lactamase and metallo beta-lactamase production among Escherichia coli and Klebsiella pneumoniae isolated from different clinical samples in a tertiary care hospital in Kathmandu, Nepal.

Krishus Nepal, Narayan Dutt Pant, Bibhusan Neupane, Ankit Belbase, Rikesh Baidhya, Ram Krishna Shrestha, Binod Lekhak, Dwij Raj Bhatta, Bharat Jha

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Detection of plasmid-mediatedInfectious diseases & immunity · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Extended-spectrum beta-lactamase-producingMicrobiology spectrum · 2024
    Article
  15. Detection of blaBMC microbiology · 2024
    Article
  16. Article
  17. Prevalence of Extended-Spectrum Beta-Lactamase (ESBL)-ProducingInternational journal of microbiology · 2024
    Article
  18. Article
  19. Prevalence ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024
    Article
  20. Microbiology spectrum · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Krishus NepalDepartment of Microbiology, GoldenGate International College, Battisputali, Kathmandu, Nepal.
Narayan Dutt PantDepartment of Microbiology, Grande International Hospital, Dhapasi, Kathmandu, Nepal. ndpant1987@gmail.com.
Bibhusan NeupaneDepartment of Microbiology, GoldenGate International College, Battisputali, Kathmandu, Nepal.
Ankit BelbaseDepartment of Microbiology, GoldenGate International College, Battisputali, Kathmandu, Nepal.
Rikesh BaidhyaDepartment of Microbiology, GoldenGate International College, Battisputali, Kathmandu, Nepal.
Ram Krishna ShresthaDepartment of Laboratory Medicine, OM Hospital and Research Center, Chabahil, Kathmandu, Nepal.
Binod LekhakCentral Department of Microbiology, Tribhuvan University, Kirtipur, Kathmandu, Nepal.
Dwij Raj BhattaCentral Department of Microbiology, Tribhuvan University, Kirtipur, Kathmandu, Nepal.
Bharat JhaDepartment of Laboratory Medicine, OM Hospital and Research Center, Chabahil, Kathmandu, Nepal.
Tribhuvan University · NPGrande International Hospital · NP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtended spectrum beta-lactamase (ESBL) and metallo beta-lactamase (MBL) production in Klebsiella pneumoniae and Escherichia coli are the commonest modes of drug resistance among these commonly isolated bacteria from clinical specimens. So the main purpose of our study was to determine the burden of ESBL and MBL production in E. coli and K. pneumoniae isolated from clinical samples. Further, the antimicrobial susceptibility patterns of E. coli and K. pneumoniae were also determined.

methodsA cross-sectional study was conducted at Om Hospital and Research Centre, Kathmandu, Nepal by using the E. coli and K. pneumoniae isolated from different clinical samples (urine, pus, body fluids, sputum, blood) from May 2015 to December 2015. Antimicrobial susceptibility testing was performed by Kirby-Bauer disc diffusion technique. Extended spectrum beta-lactamase production was detected by combined disc method using ceftazidime and ceftazidime/clavulanic acid discs and cefotaxime and cefotaxime/clavulanic acid discs. Similarly, metallo beta-lactamase production was detected by combined disc assay using imipenem and imipenem/ethylenediaminetetracetate discs. Bacteria showing resistance to at least three different classes of antibiotics were considered multidrug resistant (MDR).

resultsOf total 1568 different clinical samples processed, 268 (17.1%) samples were culture positive. Among which, E. coli and K. pneumoniae were isolated from 138 (51.5%) and 39 (14.6%) samples respectively. Of the total isolates 61 (34.5%) were ESBL producers and 7 (4%) isolates were found to be MBL producers. High rates of ESBL production (35.9%) was noted among the clinical isolates from outpatients, however no MBL producing strains were isolated from outpatients. Among 138 E. coli and 39 K. pneumoniae, 73 (52.9%) E. coli and 23 (59%) K. pneumoniae were multidrug resistant. The lowest rates of resistance was seen toward imipenem followed by piperacillin/tazobactam, amikacin and cefoperazone/sulbactam.

conclusionsHigh rate of ESBL production was found in the E. coli and K. pneumoniae isolated from outpatients suggesting the dissemination of ESBL producing isolates in community. This is very serious issue and can't be neglected. Regular monitoring of rates of ESBL and MBL production along with multidrug resistance among clinical isolates is very necessary.

Indexed as

Anti-Bacterial Agentsbeta-LactamasesBody FluidsCross-Sectional StudiesDisk Diffusion Antimicrobial TestsDrug Resistance, Multiple, BacterialEscherichia coliHumansImipenemKlebsiella pneumoniaeNepalTertiary Care CentersAnti-Bacterial Agentsbeta-LactamasesImipenemE. coliESBLK. pneumoniaeMBL

Identifiers

PMID28927454
PMCPMC5605977
OpenAlexW2754446837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.